High time for low-dose prospective clinical trials

Robert S. DiPaola, Henry J. Durivage, Barton A. Kamen

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


The article by Glode et al. in this issue reports on the empiric success, as defined by a decreased prostate specific antigen level and lack of toxicity, of metronomically delivered low-dose chemotherapy for patients with hormone-refractory prostate carcinoma. The data presented were collected as a retrospective evaluation of the medical records of patients treated with cyclophosphamide and dexamethasone who were unable to participate in Phase II drug trials or had failed previous chemotherapy regimens.

Original languageEnglish
Pages (from-to)1559-1561
Number of pages3
Issue number8
StatePublished - Oct 15 2003

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'High time for low-dose prospective clinical trials'. Together they form a unique fingerprint.

Cite this